Hines Lindsey A, Heron Jon, Zammit Stanley
Centre for Academic Mental Health, Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.
Department of Psychology, University of Bath, Bath, UK.
Addiction. 2024 Sep;119(9):1629-1634. doi: 10.1111/add.16517. Epub 2024 May 13.
High-potency cannabis has been associated with increased risk of psychosis, but a lack of prospective data hinders understanding of causality in this relationship. This study aimed to combine prospective report of cannabis use with retrospective report of potency to infer the potency of cannabis used in adolescence and explore whether use of cannabis, and the use of high-potency cannabis, in adolescence is associated with incident psychotic experiences.
Population-based birth cohort study.
United Kingdom.
n = 5570 participants who reported on any cannabis use (yes/no) age 16 and 18 years, and n = 1560 participants from this group who also retrospectively reported on cannabis potency.
In questionnaires at ages 16 and 18, individuals self-reported lifetime cannabis use, and at age 24, participants reported the type of cannabis they most commonly used in the whole time since first using cannabis. Psychotic experiences were assessed at age 24 years using the semi-structured Psychosis-Like Symptom Interview, with incident defined as new-onset occurring between ages 19 and 24 years.
Use of high-potency cannabis at age 16 or 18 was associated with twice the likelihood of experiencing incident psychotic experiences from age 19-24 (Odds Ratio 2.15, 95% Confidence Intervals 1.13-4.06). There was less evidence for an effect of any cannabis use on incident psychotic experiences (Odds Ratio 1.45, 95% Confidence Intervals 0.94-2.12).
Use of high-potency cannabis appears to be associated with increased likelihood of psychotic experiences.
高药效大麻与精神病风险增加有关,但缺乏前瞻性数据阻碍了对这种关系中因果关系的理解。本研究旨在将大麻使用的前瞻性报告与药效的回顾性报告相结合,以推断青少年使用大麻的药效,并探讨青少年使用大麻以及使用高药效大麻是否与新发精神病体验相关。
基于人群的出生队列研究。
英国。
n = 5570名在16岁和18岁时报告过任何大麻使用情况(是/否)的参与者,以及该组中的n = 1560名还回顾性报告过大麻药效的参与者。
在16岁和18岁的问卷中,个体自我报告终生大麻使用情况,在24岁时,参与者报告自首次使用大麻以来最常用的大麻类型。在24岁时使用半结构化的类精神病症状访谈评估精神病体验,新发定义为19岁至24岁之间出现的新发病例。
16岁或18岁时使用高药效大麻与19岁至24岁时出现新发精神病体验的可能性增加两倍相关(比值比2.15,95%置信区间1.13 - 4.06)。几乎没有证据表明任何大麻使用对新发精神病体验有影响(比值比1.45,95%置信区间0.94 - 2.12)。
使用高药效大麻似乎与精神病体验的可能性增加有关。